Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CLYM Climb Bio Inc.
- Stocks
- Healthcare
- NASDAQ: CLYM
Price (delayed)
$1.26
Market cap
$85.15M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.21
Enterprise value
$56.6M
Highlights
CLYM's debt has soared by 111% year-on-year but it is down by 11% since the previous quarter
Climb Bio's equity has soared by 82% YoY but it has decreased by 9% from the previous quarter
CLYM's quick ratio has plunged by 61% YoY and by 54% from the previous quarter
Climb Bio's EPS has decreased by 44% from the previous quarter
Key stats
What are the main financial stats of CLYM
Market
Valuations
Earnings
Shares outstanding
67.58M
Market cap
$85.15M
Enterprise value
$56.6M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.44
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$102.03M
Net income
-$92.98M
EBIT
-$92.98M
EBITDA
-$92.81M
Free cash flow
-$29.18M
Per share
Balance sheet
Liquidity
EPS
-$2.21
EPS diluted
-$2.21
Free cash flow per share
-$0.43
Book value per share
$2.87
Revenue per share
$0
TBVPS
$2.98
Total assets
$200.74M
Total liabilities
$7.36M
Debt
$474,000
Equity
$193.39M
Working capital
$93.24M
Debt to equity
0
Current ratio
14.25
Quick ratio
13.94
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-42.9%
Return on equity
-43.9%
Return on invested capital
-102.6%
Return on capital employed
-48%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CLYM stock price
How has the Climb Bio stock price performed over time
Intraday
5.88%
1 week
-3.08%
1 month
6.78%
1 year
-81.5%
YTD
-30%
QTD
1.61%
Financial performance
How have Climb Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$102.03M
Net income
-$92.98M
Gross margin
N/A
Net margin
N/A
CLYM's net income is down by 26% since the previous quarter
The operating income has contracted by 24% from the previous quarter
Price vs fundamentals
How does CLYM's price correlate with its fundamentals
Growth
What is Climb Bio's growth rate over time
Valuation
What is Climb Bio stock price valuation
P/E
N/A
P/B
0.44
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Climb Bio's EPS has decreased by 44% from the previous quarter
Climb Bio's equity has soared by 82% YoY but it has decreased by 9% from the previous quarter
The price to book (P/B) is 51% less than the last 4 quarters average of 0.9
Efficiency
How efficient is Climb Bio business performance
CLYM's ROIC has shrunk by 178% YoY but it is up by 31% QoQ
The company's return on equity fell by 13% QoQ
The return on assets has declined by 12% since the previous quarter
Dividends
What is CLYM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CLYM.
Financial health
How did Climb Bio financials performed over time
Climb Bio's total liabilities has soared by 149% YoY and by 39% from the previous quarter
The total assets has surged by 84% year-on-year but it has declined by 8% since the previous quarter
CLYM's debt is 100% smaller than its equity
CLYM's debt has soared by 111% year-on-year but it is down by 11% since the previous quarter
Climb Bio's equity has soared by 82% YoY but it has decreased by 9% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.